Aurinia制药公司（Aurinia Pharmaceuticals Inc）近日披露，梯瓦制药（Teva）可能最早要到2036年12月7日才能在美国市场推出沃克洛孢素（Voclosporin）的仿制药版本。
这一时间节点的设定，为Aurinia的核心产品提供了长期的市场独占保护。沃克洛孢素作为该公司研发的关键药物，其在美专利保护期得到进一步明确。
对投资者而言，这意味着未来十余年内，Aurinia在美国市场面临的仿制药竞争压力将相对有限。不过，市场分析人士也指出，专利诉讼和解条款往往包含复杂的前提条件，实际上市时间仍存在变数。
Aurinia Pharmaceuticals Inc是一家专注于自身免疫性疾病治疗的生物制药企业。此次与梯瓦达成的协议，既规避了漫长的法律纠纷，也为公司赢得了可预期的市场窗口期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.